論文

査読有り 国際誌
2020年2月25日

Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis.

Scientific reports
  • Minoru Fujimoto
  • ,
  • Tomoshige Matsumoto
  • ,
  • Satoshi Serada
  • ,
  • Yusuke Tsujimura
  • ,
  • Shoji Hashimoto
  • ,
  • Yasuhiro Yasutomi
  • ,
  • Tetsuji Naka

10
1
開始ページ
3384
終了ページ
3384
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1038/s41598-020-60450-3

Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is a global health problem. At present, prior exposure to Mtb can be determined by blood-based interferon-gamma release assay (IGRA), but active TB is not always detectable by blood tests such as CRP and ESR. This study was undertaken to investigate whether leucine-rich alpha-2 glycoprotein (LRG), a new inflammatory biomarker, could be used to assess active disease of TB. Cynomolgus macaques pretreated with or without Bacille Calmette-Guerin (BCG) vaccination were inoculated with Mtb to induce active TB. Blood was collected over time from these animals and levels of LRG as well as CRP and ESR were quantified. In the macaques without BCG vaccination, Mtb inoculation caused extensive TB and significantly increased plasma CRP and LRG levels, but not ESR. In the macaques with BCG vaccination, whereas Mtb challenge caused pulmonary TB, only LRG levels were significantly elevated. By immunohistochemical analysis of the lung, LRG was visualized in epithelioid cells and giant cells of the granulation tissue. In humans, serum LRG levels in TB patients were significantly higher than those in healthy controls and declined one month after anti-tubercular therapy. These findings suggest that LRG is a promising biomarker when performed following IGRA for the detection of active TB.

リンク情報
DOI
https://doi.org/10.1038/s41598-020-60450-3
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32099022
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042324
ID情報
  • DOI : 10.1038/s41598-020-60450-3
  • PubMed ID : 32099022
  • PubMed Central 記事ID : PMC7042324

エクスポート
BibTeX RIS